Morgan Stanley analyst Patrick Wood lowered the firm’s price target on Procept BioRobotics (PRCT) to $51 from $56 and keeps an Overweight rating on the shares. Going into 2026, MedTech “looks well-positioned on several fronts” as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for “a solid industry setup,” the analyst tells investors in a note for the group on the upcoming year.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept Biorobotics Earnings Call: Growth Amid Challenges
- Procept BioRobotics price target lowered to $50 from $55 at Piper Sandler
- Procept BioRobotics price target lowered to $50 from $85 at TD Cowen
- Procept BioRobotics price target lowered to $51 from $58 at Wells Fargo
- PROCEPT BioRobotics: Hold Rating Amid Strong Revenue but Concerns Over Utilization and Sales Cycles